1 |
Bocchini, V., Mazzolla, R., Barluzzi, R., Blasi, E., Sick, P. and Kettenmann, H. (1992) An immortalized cell line expresses properties of activated microglial cells. J. Neurosci. Res. 31, 616-621.
DOI
ScienceOn
|
2 |
Dev, R., Srivastava, P. K., Iyer, J. P., Dastidar, S. G. and Ray, A. (2010) Therapeutic potential of matrix metalloprotease inhibitors in neuropathic pain. Expert Opin. Investig. Drugs 19, 455-468.
DOI
|
3 |
Gearing, A. J., Beckett, P., Christodoulou, M., Churchill, M., Clements, J.,M., Crimmin, M., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., Leber, T. M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomasv W., Wells, G., Wood, L. M. and Woolley, K. (1995) Matrix metalloproteinases and processing of pro-TNF-alpha. J. Leukoc. Biol. 57, 774-777.
DOI
|
4 |
Hu, J., Van den, Steen P. E., Sang, Q. X. A. and Opdenakker, G. (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Dicsov. 6, 480-498.
DOI
ScienceOn
|
5 |
Javaid, M. A., Abdallah, M. N., Ahmed, A. S. and Sheikh, Z. (2013) Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview. Acta Neurol. Belg. 113, 381-390.
DOI
|
6 |
Kataoka, H. (2009) EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J. Dermatol. Sci. 56, 148-153.
DOI
|
7 |
Lee, E. J., Han, J. E., Woo, M. S., Shin, J. A., Park, E. M., Kang, J. L., Moon, P. G., Baek, M. C., Son, W. S., Ko, Y. T., Choi, J. W. and Kim, H. S. (2014) Matrix metalloproteinase-8 plays a pivotal role in neuroinflammation by modulating TNF- activation. J. Immunol. 193, 2384-2393.
DOI
|
8 |
Li, N. G., Tang, Y. P., Duan, J. A. and Shi, Z. H. (2014) Matrix metalloproteinase inhibitors: a patent review (2011-2013). Expert Opin. Ther. Pat. 24, 1039-1052.
DOI
|
9 |
Mayhan, W. G. (2002) Cellular mechanisms by which tumor necrosis factor-a produces disruption of the blood-brain barrier. Brain Res. 927, 144-152.
DOI
ScienceOn
|
10 |
McCoy, M. and Tansey, M. G. (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 5, 45.
DOI
ScienceOn
|
11 |
Minond, D., Cudic, M., Bionda, N., Giulianotti, M., Maida, L., Houghten, R. A. and Fields, G. B. (2012) Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates. J. Biol. Chem. 287, 36473-36487.
DOI
ScienceOn
|
12 |
Morancho, A., Rosell, A., Garcia-Bonilla L. and Montaner J. (2010) Matrix metalloproteinase and stroke infarct size: role for anti-inflammatory treatment. Ann. N. Y. Acad. Sci. 1207, 123-133.
DOI
|
13 |
Moss, M. L., Jin, S. L., Milla, M. E., Bickett, D. M., Burkhart, W., Carter, H. L., Chen, W. J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., Kost, T. A., Lambert, M. H., Leesnitzer, M. A., McCauley, P., McGeehan, G., Mitchell, J., Moyer, M., Pahel, G., Rocque, W., Overton, L. K., Schoenen, F., Seaton, T., Su, J. L. and Becherer, J. D. (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385, 733-736
DOI
|
14 |
Rosenberg, G. A. (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 8, 205-216.
DOI
|
15 |
Tian, L., Ma, L., Kaarela, T. and Li, Z. (2012) Neuroimmune crosstalk in the central nervous system and its significance for neurological diseases. J. Neuroinflammation 9, 155.
DOI
|
16 |
Aggarwal, B. B. (2003) Signaling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745-756.
DOI
ScienceOn
|
17 |
Verma, R. P. and Hansch, C. (2007) Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs. Bioorg. Med. Chem. 15, 2223-2268
DOI
|
18 |
Verslegers, M., Lemmens, K., Hove, I. V. and Moons, L. (2013) Matrix metalloproteinase-2 and-9 as promising benefactors in development, plasticity and repair of the nervous system. Prog. Neurobiol. 105, 60-78.
DOI
ScienceOn
|
19 |
Woo, M. S., Park, J. S., Choi, I. Y., Kim, W. K. and Kim, H. S. (2008) Inhibition of MMP-3 or-9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J. Neurochem 106, 770-780.
DOI
ScienceOn
|
20 |
Agrawal, S. M., Lau, L. and Yong V. W. (2008) MMPs in the central nervous system: where the good guys go bad. Semin. Cell Dev. Biol. 19, 42-51.
DOI
ScienceOn
|
21 |
Asai, M., Hattori, C., Szabo, B., Sasagawa, N., Maruyama, K., Tanuma, S. and Ishiura, S. (2003) Putative function of ADAM9, ADAM10, and ADAM17 as APP -secretase. Biochem. Biophys. Res. Commun. 301, 231-235.
DOI
|
22 |
Bahia M. S. and Silakari O. (2010) Tumor necrosis factor alpha converting enzyme: an encouraging target for various inflammatory disorders. Chem. Biol. Drug Des. 75, 415-443.
DOI
|
23 |
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., Nelson, N., Boiani, N., Schooley, K. A., Gerhart M., Davis, R., Fitzner, J. N., Johnson, R. S., Paxton, R. J., March, C. J. and Cerretti, D. P. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729-733.
DOI
ScienceOn
|
24 |
Moss, M. L., Sklair-Tavron, L. and Nudelman, R. (2008) Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 4, 300-309.
|
25 |
Candelario-Jalil, E., Yang, Y. and Rosenberg, G. A. (2009) Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158, 983-994.
DOI
ScienceOn
|
26 |
Lee, E. J., Woo, M. S., Moon, P. G., Baek, M. C., Choi, I. Y., Kim, W. K., Junn, E. and Kim, H. S. (2010) -Synuclein activates microglia by inducing the expressions of matrix metalloproteases and the subsequent activation of protease-activated receptor-1. J. Immunol. 185, 615-623.
DOI
|